1. Introduction {#s0005}
===============

Superficial fungal infections are common diseases at all ages and for both sexes. There is a wide variation of infection type (pityriasis versicolor, etc.), and different pathogens may be observed as causative agents. Treatment options may change according to the severity of the disease, the physician's choice and the medical status of the patient ([@b0210]).

More than 200 *Candida* species were identified and about 30 species of them cause human infections. The infection spectrum shows a wide variability from superficial to invasive infections. *Candida albicans* colonizes the skin, genital, and/or intestinal mucosa and is the most frequently isolated species from infections, but species distribution may vary worldwide. Although invasive *Candida* infections get all attention, skin and soft tissue infections have a wide space among *Candida* infections ([@b0210], [@b0170], [@b0070]).

There are many options on treating superficial fungal infections, but unclearity on optimal treatment period, application type and dosage may result with low efficacy ([@b0065]). Therefore, the studies have focused on the development of alternative dosage forms. Structural modifications on azoles showed high *in vitro* effects against *C. albicans*, whereas correlation on *in vivo* and *in vitro* effectiveness of azole derivates is questionable ([@b0130]). On the other hand, azoles are still in use and many studies showed high efficiency even *in vivo* ([@b0075]).

The azole antifungals are the most widely used class in treatment of candidiasis. Especially for invasive candidiasis, there is an emergent situation on antifungal resistance to azoles. But, for superficial candidiasis, the data is very limited. Azole resistance is strongly related with administration route, and systemic application is more inclined to this condition. However, the situation against oxiconazole nitrate (ON) is a mystery. Although resistance mechanisms against ON might be similar to the others, virulence of *Candida* species causing skin infections is significantly different from ones causing invasive infections, which is related with antifungal resistance ([@b0215], [@b0150]).

Oxiconazole active substance was selected from this group because it has low-medium molecular weight, high permeability, no deep irritation, high local bioavailability and good compatibility with polymers. Transdermally administered thermosensitive gels are new drug delivery systems that have been studied frequently since they have *in situ* activity depending on the temperature ([@b0175]). The thermosensitive gels are superior to the conventional gels in terms of stability, ease of use for patients, improved local bioavailability, and efficacy at low doses, easy preparation and low production costs.

In this study we aimed to develop thermosensitive gel formulation (TGF) of ON showing antifungal activity, which explores gelling at body temperature when it is applied to the skin. After performing the characterization studies of the formulation, we tried to determine its effectiveness by comparing our findings with ON solution using time-dependent analysis.

2. Materials and methods {#s0010}
========================

2.1. Materials {#s0015}
--------------

ON was kindly donated by the Deva Pharmaceutical Industry (Turkey) for the studies. Poloxamer 407 was purchased from Sigma-Aldrich Co (St Louis, MO, USA). All other chemicals were used as reagent grade without further purification.

2.2. Preparation of TGF {#s0020}
-----------------------

The TGF was prepared by "cold method" ([@b0020]). The poloxamer 407 solution was prepared at 4 °C and it was left to stand overnight for the loss of foam formation. ON was dissolved in a mixture of ethanol and polyethylene glycol 400 (Sigma-Aldrich Co, St Louis, MO, USA) and added to the poloxamer 407 solution slowly and by being stirred at 4 °C. A sufficient amount of distilled water was used in preparation of the solution. The details of all components of formulation are shown in [Table 1](#t0005){ref-type="table"}. In the process of mixing the solutions, ice battery was used to keep the ambient temperature at 4 °C. The mixture was allowed to stand at 4 °C overnight to begin *in vitro* assays.Table 1The components and concentrations of thermosensitive gel formulation.ContentsConcentration (%)Oxiconazole nitrate1 (w/v)Poloxamer 40722 (w/v)Ethanol18 (v/v)PEG 4009 (v/v)Distilled waterq.s.

2.3. The preparation of ON and TGF solutions {#s0025}
--------------------------------------------

Stock solution of ON in dimethyl sulfoxide (DMSO) (Merck Millipore, MA, USA) in concentration of 12.8 mg/mL was prepared. Stock solutions of TGF in DMSO can also be prepared with the same last concentration of ON. 50 µL from each solutions were completed to 20 mL with Roswell Park Memorial Institute 1640 medium (Sigma-Aldrich Co, MO, USA) and 400-fold serial dilutions were applied to final concentration of 32 µg/mL. Roswell Park Memorial Institute medium, which is commonly referred to as RPMI medium or RPMI 1640, is a form of medium used in cell culture and tissue culture used to grow a variety of mammalian cell lines. RPMI 1640 uses a bicarbonate buffering system and differs from most of the mammalian cell culture media in its typical pH 8 formulation.

2.4. The characterization studies and rheological and mechanical properties of formulation {#s0030}
------------------------------------------------------------------------------------------

### 2.4.1. FT-IR spectrum of TGF {#s0035}

Spectra of all the compounds used in the formulation were obtained by scanning over a wide range of 650--4000 cm^−1^ using FT-IR spectrophotometer (Perkin Elmer, MA, USA). The peaks of the polymers used in the formulation were analyzed ([@b0080]). The solution state of the TGF at 4 °C was compared with the gel state at 35 °C by FT-IR spectrophotometer ([@b0155]).

### 2.4.2. The determination of sol-gel transition temperature and time of TGF {#s0040}

The sol-gel transition temperature of TGF was determined using Haake Viscotester 7 Plus viscosimetry device (Thermo-Fisher Scientific, MA, USA) with R7 spindle at 0.1 rpm. The temperature was changed from 4 °C to 45 °C increasing by 0.5 °C per minute. The viscosity changes of the formulation were recorded. The time was calculated since the beginning of a significant increase in viscosity and the middle point of the region where the increase in viscosity happened due to the increase of the temperature was the basis of the calculation of the sol-gel transformation of the prepared TGF.

### 2.4.3. The viscosity, hardness and adhesion measurements of TGF {#s0045}

Haake Viscotester 7 Plus device was used in the rheological examination of the TGF. The study by [@b0035] was modified and the measurements were done by increasing 0.5 °C/min between 0.1 °C and 45 °C at 0.1 rpm R7 spindle and viscosities were determined. The study by [@b0220] was modified and the hardness and adhesion measurements of the TGF were performed on software-assisted H5KS Benchtop Tensilometer (Tinius Olsen, Redhill, UK). The measurements started at 35 °C after the completion of the sol-gel transition of the formulation. The hard silicone probe 20 mm in diameter was immersed into the gel 15 mm at rate of 10 mm/min to evaluate the hardness of the prepared TGF. Then, the adhesion and elasticity measurements were analyzed and recorded while the probe was leaving from the gel surface with the same parameters.

*2.5*. *In vitro* antifungal analysis {#s0050}
-------------------------------------

### 2.5.1. The preparation of *Candida* strains {#s0055}

The strains of *Candida albicans* ATCC 10231, *Candida krusei* ATCC 6258 and *Candida parapsilosis* ATCC 22,019 were prepared to 0.5 MacFarland turbidity standard (1--5 × 10^6^ CFU/mL) in 0.9% NaCl. These solutions were 1000-fold diluted to 1--5 × 10^3^ CFU/mL.

### 2.5.2. Broth macrodilution {#s0060}

To get reliable data on *in vitro* antifungal efficiency of ON and TGF, an antifungal analysis was applied within a broth macrodilution method according to [@b0050], [@b0055] standard guidelines. Due to the lack of information about ON in the guidelines, modified azole standards and methods were used. As a solvent, DMSO is a best choice except fluconazole, which also worked excellently for ON and TGF, as previously reported ([@b0120]). Because of the evaluation of dilution range is not clear for oxiconazole, the widest range in CLSI guidelines (0.016--128 mg/L) with 14 serial dilutions and also positive and negative control tubes were applied. Following the addition of RPMI medium and *Candida* solutions, final concentrations were 100-fold diluted. The tubes were incubated in ambient atmosphere and 37 °C temperature for 24 h, and visual evaluation was done to detect minimum inhibitory concentration (MIC) levels ([@b0050], [@b0105]). Furthermore, to evaluate the minimum fungicidal concentration (MFC), visual turbidity-detected tubes were additionally inoculated to standard methods agar (SMA) (Thermo-Fisher Scientific, MA, USA) quantitatively (1 μL, 10 μL), as applied previously by [@b0025]. For MFC, fungicidal rate of ≥98% is necessary and according to this data, tubes with a maximum of 20 colonies for 10 μL and 2 colonies for 1 μL inoculation were accepted as MFC ([@b0060], [@b0015], [@b0010], [@b0195], [@b0100]).

### 2.5.3. The time-dependent fungicidal activity {#s0065}

The method modified from CLSI M26-A guidelines was applied to compare the fungicidal activity alterations of ON and TGF in time ([@b0045]). 40 μL from each previously prepared stock solutions were added to 3960 μL RPMI media (100-fold diluted). Then, 2.225 mL from this solution were added into 29.775 mL RPMI media, which results final concentrations to 8.9 μg/mL. With the same methodology in broth macrodilution, serial dilutions were made at 8.9, 4.45, 2.225, 1.1125, 0.5563, 0.2781 and 0.1391 μg/mL final concentrations.

Solutions of *Candida* species ATCC 10,231 at 0.5 MacFarland turbidity standard (1--5 × 10^6^ CFU/mL) was 10-fold serially diluted. After combining fungal and antifungal solutions, the concentrations of ON and TGF were finally at 8, 4, 2, 1, 0.5, 0.25 and 0.125 μg/mL.

At 0, 4, 8, 16 and 24th h, 1 μL and 10 μL from each tube were quantitatively inoculated to SMA and plates were incubated in ambient atmosphere at 35 °C temperature for 24 h. Colonies were counted and noted ([@b0025], [@b0045], [@b0160], [@b0040], [@b0185], [@b0090]).

3. Results and discussion {#s0070}
=========================

Although various studies of different dosage forms of imidazole derivatives are available, studies on ON are very limited ([@b0165]). Transdermally administered thermosensitive gels are new drug delivery systems that have been studied. Thermal sensitive carrier systems have a number of advantages due to their suitability for both lipophilic and hydrophilic active agents, the presence of low systemic side effects, the specificity of the application site and the possibility of controlled release. The thermosensitive gels which are solid when applied to body at the temperature of the skin surface have excellent thermal conversion and have an advantage of having a high bioadhesive activity ([@b0140], [@b0030], [@b0005]). In this study, we aimed to develop a TGF of ON for antifungal activity.

3.1. Temperature of the sol-gel transition {#s0075}
------------------------------------------

The temperature was gradually increased in the study of transition from liquid to gel form. The results are shown in [Fig. 1](#f0005){ref-type="fig"}. The gelling temperature is measured as a value close to the average surface temperature of the human skin ([@b0200]). The gelation temperature and gelation time are shown in the [Table 2](#t0010){ref-type="table"}. It was observed that the use of ethanol and PEG 400 in the formulation caused the increased gelation temperature ([@b0085]), while the use of poloxamer 407 at 22% would reduce the gelation temperature. By using the ratios of the formula components which is shown in [Table 1](#t0005){ref-type="table"}, it is possible to obtain the optimum formula for body surface temperature by changing the ratios of ingredients of the formulationFig. 1Viscositiy and T~sol-gel~ measurements of TGF.Table 2The gelation temperature and the gelation time of the formulation.Gelation temperature (°C) ± SDGelation time (sec) ± SD33.01 ± 0.025343.100 ± 0.177

3.2. Viscosity, hardness and adhesion {#s0080}
-------------------------------------

The amount of gelling agent in a formulation is very crucial for its mechanical properties. The gel hardness with the association of gel adhesiveness indicates the gel applicability and this may be indicative to obtain the retention time in the application area. This is also directly related to the polymer concentration and is a very important parameter in wound healing ([@b0205], [@b0135]). The temperature of the formulation was checked before starting the analysis of this study. The adhesion measurement of the TGF is shown in [Fig. 2](#f0010){ref-type="fig"} and the hardness measurements are shown in [Fig. 3](#f0015){ref-type="fig"}. The viscosity changes obtained by gradually increasing the temperature are shown in the [Fig. 1](#f0005){ref-type="fig"}. The hardness and adhesion measurements were carried out after the gelation. The results are shown in [Table 3](#t0015){ref-type="table"}. In the study of [@b0145], it was observed that the increase of the concentration of poloxamer 407 is directly proportional to increase of adhesion and hardness. This is compatible with our findings.Fig. 2The adhesion measurements of TGF.Fig. 3The hardness measurements of TGF.Table 3Viscositiy of sol-gel, hardness and adhesion properties of the formulation (n = 3).Viscositiy 4 °C (pa·s)Viscositiy 33 °C (pa·s)Hardness (N)Adhesion (N)30.94 ± 0.55726 ± 2.60.5001 ± 0.020.4855 ± 0.1

3.3. FT-IR spectroscopy {#s0085}
-----------------------

Individual FT-IR spectra of the compounds at the formula were determined. When the spectra of the components in the formulation were examined, it was found that some peaks are not detected due to the decrease in concentration with the presence of water in the formulation. However, it was found that the characteristic peaks of ON and poloxamer 407 were preserved ([@b0080]). FT-IR spectrums before and after gelation were superimposed to observe any difference for comparison. It was investigated whether there was any difference after gelling. As a result, it was observed that the spectra overlapped in great scale and there isn\'t any peak appeared. However, with the increase in temperature, it shows that there are slightly differences in 1413, 2917 and 3295 cm^−1^. This can be explained with the evaporation of the water after gelation. This result reveals the fact that the temperature does not cause any disruption to the ingredients in the formulation and the process of the consistent gelationis reversible. It is observed that FT-IR spectrometer analysis results are compatible with the study by [@b0155]. The results are shown in [Fig. 4](#f0020){ref-type="fig"}.Fig. 4A; FT-IR spectrum of oxiconazole nitrate, B; FT-IR spectrum of PEG 400, C; FT-IR spectrum of poloxamer 407, D; FT-IR spectrum of thermosensitive gel formulation (TGF) at 4 °C, E; the overlapped FT-IR spectrum of thermosensitive gel formulation (TGF) at 4 °C (solution) and 35° (gel).

*3.4*. *In vitro* antifungal analysis {#s0090}
-------------------------------------

Broth macrodilution, a standardized method, is a necessity to get true MIC and MFC data and to evaluate exact susceptibilities to ON and TGF. [Table 4](#t0020){ref-type="table"} shows MIC and MFC levels of ON and TGF. According to broth macrodilution and serial quantitative inoculations, ON and TGF showed similar antifungal activity results. Although same MIC levels were observed, *in vivo* studies must be evaluated to verify this conclusion. MIC results do not always correlate with clinical outcome, and for this reason, MFC testing generally gives supportive data. Studies indicate that MFC has a promising potential with stated clinical correlation ([@b0190]). In our study, despite same MIC levels, a higher MFC level was detected for ON (128 μg/mL) than for TGF (64 μg/mL). This situation may be caused by ethanol which is used to solve ON, and it seems this is an advantage of TGF over purely tested ON on antifungal activity ([@b0180]). [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"} show the time-dependent antifungal activities of TGF and ON. TGF did not lose their activity and was also correlated with the activity of ON.Fig. 5The time-dependent antifungal activity profile of TGF (*C. albicans* ATCC 10231).Fig. 6The time-dependent antifungal activity profile of ON (*C. albicans* ATCC 10231).Table 4MIC and MFC values of ON and TGF.MIC (µg/mL)MFC (µg/mL)ONTGFONTGF*C. albicans*0.250.256464*C. krusei*0.1250.12512864*C. parapsilosis*0.1250.1256464

Both [@b0050], [@b0055], [@b0105] guidelines recommend the usage of DMSO as a solvent in susceptibility testing of water-insoluble drugs. However, studies indicated that DMSO in low concentrations (\<4%) may cause alterations (both as inducer or suppressive) on the growth of *Candida* species, which may affect susceptibility results. On the other hand, researchers claimed that there is an effect on yeast growth, but this effect may not be observed on MIC levels, which makes these alterations controversial ([@b0125]). To check DMSO effect on *Candida* growth, we used same concentrations of DMSO in each tested tube and tests were done in the same conditions. According to our study, this kind of effect can be disregarded and we do not think that this is a major limitation.

Potency takes a primary place in susceptibility tests. Both [@b0050], [@b0055], [@b0105] guidelines have a necessity of calculation with potency. Unfortunately, it was unable to reach potency of ON from the manufacturer guidelines and academic articles, so the effect of potency results was not given in this study. This limitation may cause a problem related with actual antifungal activity of ON such as the underestimation of MIC levels. Even if it was true, this would not affect the results of the comparison between TGF and ON.

Visual turbidity determination as in CLSI may show a difference with spectrophotometric measurement (EUCAST) ([@b0115]), but researchers state that there is no statistically meaningful alterations between these two methods ([@b0190], [@b0095]).

Another MIC evaluation is "epidemiological cut-off value (ECOFF)", which is a very important parameter for non-wild type strains. These microorganisms may show acquired or mutational resistance to the antifungal agent that is observed phenotypically ([@b0110]). Since this condition might cause treatment failures, it is crucial to test a novel drug for various types of strains, even of a single species, to define ECOFF values and its potential in treatment. As we have only studied wild-type strains, this can be a limitation. However, ON is not a novel drug and we have just studied it on different formulations of a known agent, so it is possible to comment that this limitation can be underestimated. To obtain reliable data on this ECOFF issue, various types of strains should be tested with all our formulations.

Another issue is "tissue-treated vs. non-tissue-treated" microdilution plates, which is commented in [@b0105] worksheets. Although there is insufficient data to decide whether it is a problem or not ([@b0110]), it should be noted that our study based on CLSI guidelines can be improved according to this notification.

4. Conclusion {#s0095}
=============

By examining physicochemical properties of ON, it is observed that the solubility in water is very slightly, so it is difficult to develop a poloxamer-based TGF, which has good water solubility. We developed a TGF containing ON and carried out the characterization study. Characterization studies and time-dependent antifungal activity analysis showed that ON did not show any incompatibility with the adjuvants in the formulation and also retained its activity on *C. albicans* strain.

Commercial ON products have already proven to be efficient, but the data we found supports that TGF can be a good alternative to reach the same success. It is crucial to perform long-term treatment studies, especially for drug-resistant species. The obtained data are thought to be valuable, due to the lack of such studies in the literature. It is also necessary to expand the sample size and perform human researches to evaluate the applicability and patient comfort and to observe same success on patients. We believe that TGF of ON will bring a new approach to the treatment of candidiasis.
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